Publications by authors named "Ryosuke Oki"

Claim this Profile
T
The first case of fusion-positive malignant spindle cell sarcoma of the head and neck responsive to selpercatinib.
Takehiro Nakao, Naoki Fukuda, Xiaofei Wang, Ryosuke Oki, Tetsuya Urasaki

Int Cancer Conf J· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sporadic medullary thyroid carcinoma with a rare RET transmembrane domain mutation (A641R) that responds to selpercatinib.
Naoki Fukuda, Kazuhisa Toda, Tomohiro Chiba, Ippei Fukada, Seiichi Mori, Ryosuke Oki

Oncologist· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the diagnostic performance of brachial plexus ultrasound in amyotrophic lateral sclerosis.
Hiroki Yamazaki, Naoko Takamatsu, Tomoyasu Matsubara, Miki Tani, Koji Fukushima, Ryosuke Oki

Clin Neurophysiol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Excellent Clinical and Radiological Response Pattern to Pembrolizumab in a Patient With Metastatic Adrenocortical Carcinoma and Lynch Syndrome.
Yuki Shimozawa, Yosuke Yasuda, Emiko Sugawara, Ryosuke Oki, Kosuke Takemura

IJU Case Rep· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevailing challenges in personalized treatment for metastatic renal cell carcinoma: a narrative review.
Ryosuke Oki, Kosuke Takemura, Tetsuya Urasaki, Ryo Fujiwara, Noboru Numao

Expert Rev Anticancer Ther· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic significance of body mass index in patients with metastatic renal cell carcinoma receiving first-line therapies.
Keigo Sato, Kosuke Takemura, Ryosuke Oki, Tetsuya Urasaki, Yusuke Yoneoka

Urol Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Confirmatory diagnosis and successive chemotherapeutic treatments of metastatic skeletal sarcoma: A case report.
Tetsuya Urasaki, Makiko Ono, Kyoko Yamashita, Taisuke Tanizawa, Yuki Togashi, Ryosuke Oki, Naoki Fukuda

Oncol Lett· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of adjuvant nivolumab after radical surgery for high-risk urothelial carcinoma: a preliminary report of real-world data from a single institution.
Yosuke Yasuda, Noboru Numao, Tetsuya Urasaki, Ryosuke Oki, Tomohiko Oguchi

Int J Clin Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ultra-high dose methylcobalamin and other emerging therapies for amyotrophic lateral sclerosis.
Ryuji Kaji, Yuishin Izumi, Ryosuke Oki

Curr Opin Neurol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical impact of proteinuria on renal function and treatment outcomes in patients with radioiodine-refractory thyroid cancer treated with lenvatinib.
Naoki Fukuda, Kazuhisa Toda, Hirotaka Suto, Ryosuke Oki, Xiaofei Wang, Hiroki Mitani

Endocr J· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A case of sequential medical therapy for advanced ureteral cancer in Li-Fraumeni syndrome.
Minami Une, Ryo Fujiwara, Arisa Ueki, Ryosuke Oki, Tetsuya Urasaki

IJU Case Rep· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Paclitaxel plus Carboplatin versus Observation in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma of the Head and Neck.
Naoki Fukuda, Ryosuke Oki, Hirotaka Suto, Xiaofei Wang, Tetsuya Urasaki, Hiroki Mitani

Oncology· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Significance of Immune-related Adverse Events in Metastatic Renal Cell Carcinoma Patients Treated With Immune-checkpoint-inhibitors.
Yosuke Yasuda, Ryo Fujiwara, Tomohiko Oguchi, Yoshinobu Komai, Noboru Numao, Ryosuke Oki

Cancer Diagn Progn· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical characteristics of sarcoma cases in which long-term disease control was achieved with trabectedin treatment: A retrospective study.
Akihiro Ohmoto, Kenji Nakano, Naoki Fukuda, Xiaofei Wang, Tetsuya Urasaki, Ryosuke Oki

PLoS One· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Geriatric Nutritional Risk Index as a Predictor of Prognosis in Metastatic Renal Cell Carcinoma Treated with Nivolumab.
Ryo Fujiwara, Takeshi Yuasa, Shinya Yamamoto, Motohiro Fujiwara, Kosuke Takemura, Ryosuke Oki

Nutr Cancer· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A radiological complete response to pembrolizumab in a patient with metastatic upper urinary tract urothelial cancer and Lynch syndrome.
Ryosuke Oki, Tetsuya Urasaki, Arisa Ueki, Kentaro Inamura, Yoshinobu Komai

IJU Case Rep· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Exploratory Trial of EPI-589 in Amyotrophic Lateral Sclerosis (EPIC-ALS): Protocol for a Multicenter, Open-Labeled, 24-Week, Single-Group Study.
Shotaro Haji, Koji Fujita, Ryosuke Oki, Yusuke Osaki, Ryosuke Miyamoto, Naoki Atsuta

JMIR Res Protoc· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial.
Keiko Imamura, Yuishin Izumi, Makiko Nagai, Kazutoshi Nishiyama, Yasuhiro Watanabe, Ryosuke Oki

EClinicalMedicine· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.
Ryosuke Oki, Yuishin Izumi, Koji Fujita, Ryosuke Miyamoto, Hiroyuki Nodera, Hiroshi Nokihara, Naoki Atsuta

JAMA Neurol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A proposed clinical scoring system for initiation of lenvatinib treatment in radioiodine-refractory thyroid cancer patients.
Naoki Fukuda, Kazuhisa Toda, Shohei Udagawa, Akihiro Ohmoto, Ryosuke Oki, Hiroki Mitani

Endocrine· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-Systemic Chemotherapy Prognoses of Recurrent/Metastatic Soft Tissue Sarcoma Patients with Retroperitoneal/Intra-Abdominal Origin versus Those with Extremities/Trunk Origin.
Kenji Nakano, Naoki Fukuda, Yasuyoshi Sato, Tetsuya Urasaki, Akihiro Ohmoto, Ryosuke Oki

Oncology· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent Advances in Medical Therapy for Urological Cancers.
Takeshi Yuasa, Tetsuya Urasaki, Ryosuke Oki

Front Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neuroendocrine Neoplasms of the Breast: The Latest WHO Classification and Review of the Literature.
Yukinori Ozaki, Sakiko Miura, Ryosuke Oki, Teppei Morikawa, Keita Uchino

Cancers (Basel)· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reliability and validity of D-dimer monitoring for pulmonary thromboembolism in patients with unresectable, advanced or recurrent colorectal cancer treated with bevacizumab.
Dan Kanehira, Masashi Kusakabe, Sachio Shimizu, Junichi Shimizu, Jinshi Irikuchi, Ryosuke Oki

Mol Clin Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients.
Keiko Imamura, Yuishin Izumi, Haruhiko Banno, Ryuji Uozumi, Satoshi Morita, Ryosuke Oki

BMJ Open· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis